Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $650.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective increased by Wells Fargo & Company from $550.00 to $650.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the pharmaceutical company’s stock.

VRTX has been the subject of several other reports. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Cantor Fitzgerald raised their price objective on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a research report on Tuesday. Truist Financial lifted their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 11th. They issued an “overweight” rating and a $560.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $596.44.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $542.50 on Tuesday. The stock has a market cap of $137.69 billion, a P/E ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $522.81 and its two-hundred day moving average price is $481.42. Vertex Pharmaceuticals has a twelve month low of $406.67 and a twelve month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.80 EPS. As a group, equities analysts predict that Vertex Pharmaceuticals will post 16.50 EPS for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of hedge funds have recently made changes to their positions in VRTX. Guidance Capital Inc. raised its holdings in shares of Vertex Pharmaceuticals by 0.9% during the third quarter. Guidance Capital Inc. now owns 2,230 shares of the pharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 19 shares in the last quarter. Bangor Savings Bank boosted its holdings in Vertex Pharmaceuticals by 0.4% in the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock valued at $2,220,000 after acquiring an additional 20 shares in the last quarter. Trust Point Inc. boosted its holdings in Vertex Pharmaceuticals by 2.7% in the second quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after acquiring an additional 21 shares in the last quarter. Integrated Advisors Network LLC increased its position in Vertex Pharmaceuticals by 1.4% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock valued at $850,000 after purchasing an additional 22 shares during the period. Finally, Glenview Trust Co increased its position in Vertex Pharmaceuticals by 0.3% during the 3rd quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company’s stock valued at $3,541,000 after purchasing an additional 22 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.